We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+23.6%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$138M
AUM Growth
-$12.5M
Cap. Flow
-$25.1M
Cap. Flow %
-18.28%
Top 10 Hldgs %
79.11%
Holding
58
New
8
Increased
6
Reduced
5
Closed
6

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$41.9M
2
BMY.RT
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
+$1.82M
3
CFRX
ContraFect Corporation
CFRX
+$942K
4
QGEN icon
Qiagen
QGEN
+$701K
5
GOSS icon
Gossamer Bio
GOSS
+$604K

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$69.5M
2
DOVA
Dova Pharmaceuticals, Inc. Common Stock
DOVA
+$1.4M
3
EQM
EQM Midstream Partners, LP
EQM
+$1.39M
4
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$604K
5
DERM
Dermira, Inc.
DERM
+$345K

Sector Composition

Rank Sector Weight
1 Healthcare 94.64%
2 Energy 1.7%
3 Consumer Staples 0.09%
4 Materials 0.06%
5 Consumer Discretionary 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WMGI
26
DELISTED
Wright Medical Group Inc
WMGI
$914K 0.66%
30,000
– –
MYGN icon
27
Myriad Genetics
MYGN
$557M
$817K 0.59%
30,000
– –
QGEN icon
28
Qiagen
QGEN
$8.39B
$676K 0.49%
+18,861
New +$701K
ODT
29
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$649K 0.47%
20,000
– –
CORT icon
30
Corcept Therapeutics
CORT
$9.83B
$605K 0.44%
50,000
– –
ACAD icon
31
Acadia Pharmaceuticals
ACAD
$4.32B
$599K 0.44%
14,000
– –
PXD
32
DELISTED
Pioneer Natural Resource Co.
PXD
$575K 0.42%
3,800
– –
BHVN
33
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$544K 0.4%
+10,000
New +$495K
KALV
34
DELISTED
KalVista Pharmaceuticals
KALV
$534K 0.39%
30,000
– –
GOSS icon
35
Gossamer Bio
GOSS
$71.2M
$469K 0.34%
+30,000
New +$604K
UTHR icon
36
United Therapeutics
UTHR
$22.4B
$440K 0.32%
+5,000
New +$440K
XNCR icon
37
Xencor
XNCR
$1.4B
$423K 0.31%
12,300
– –
VYGR icon
38
Voyager Therapeutics
VYGR
$186M
$419K 0.3%
30,000
– –
PGNY icon
39
Progyny
PGNY
$2.5B
$412K 0.3%
+15,000
New +$360K
FOLD
40
DELISTED
Amicus Therapeutics
FOLD
$370K 0.27%
38,000
– –
SIEN
41
DELISTED
Sientra, Inc.
SIEN
$358K 0.26%
4,000
– –
LXRX icon
42
Lexicon Pharmaceuticals
LXRX
$1.02B
$332K 0.24%
80,000
– –
VCYT icon
43
Veracyte
VCYT
$4.59B
$301K 0.22%
10,767
-5,000
-32% -$129K
APLS
44
DELISTED
Apellis Pharmaceuticals
APLS
$245K 0.18%
+8,000
New +$221K
OVV icon
45
Ovintiv
OVV
$16.4B
$232K 0.17%
9,910
– –
DRNA
46
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$220K 0.16%
10,000
-30,000
-75% -$604K
CLR
47
DELISTED
CONTINENTAL RESOURCES INC.
CLR
$206K 0.15%
6,000
-2,000
-25% -$62.1K
TGTX icon
48
TG Therapeutics
TGTX
$8.33B
$167K 0.12%
15,000
– –
YTEN
49
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
$130K 0.09%
790
+661
+512% +$210K
LTHM
50
DELISTED
Livent Corporation
LTHM
$86K 0.06%
10,000
– –
1
2
3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q4 2019 Portfolio in Review

As of Q4 2019, Birchview Capital held 58 positions worth $138M, down 8.3% from $150M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Birchview Capital withdrew a net $25.1M in Q4 2019, closing 6 positions and reducing 5 holdings. Its most notable exit was Celgene Corp, an estimated $69.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Energy and Consumer Staples.

Against the trend, Birchview Capital opened a new position in Bristol-Myers Squibb Company Contingent Value Rights worth $2.11M.

  • Birchview Capital's largest Q4 2019 buy was Bristol-Myers Squibb Company Contingent Value Rights: 699,648 shares worth $2.11M.
  • Birchview Capital added most to Bristol-Myers Squibb in Q4 2019, an estimated $41.9M increase.
  • Birchview Capital's biggest Q4 2019 reduction was EQM Midstream Partners, LP, cutting an estimated $1.39M.
  • Birchview Capital fully exited Celgene Corp in Q4 2019, selling an estimated $69.5M.
  • Birchview Capital's ten largest holdings make up 79% of its $138M portfolio in Q4 2019.
  • Birchview Capital opened 8 new positions and closed 6 in Q4 2019.
  • Birchview Capital's portfolio value fell 8.3% quarter-over-quarter to $138M.

Based on Birchview Capital's 13F filing for Q4 2019, filed 12 Feb 2020.